Kyntra Bio Total Assets Growth & History (KYNB)
Kyntra Bio's total assets was $119.6M for fiscal 2025.
View full Kyntra Bio company overviewKyntra Bio annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $119.6M | −$94.9M | −44.25% |
| 2024 | 2024-12-31 | $214.5M | −$209.0M | −49.35% |
| 2023 | 2023-12-31 | $423.5M | −$186.6M | −30.58% |
| 2022 | 2022-12-31 | $610.1M | −$163.7M | −21.16% |
| 2021 | 2021-12-31 | $773.8M | −$53.0M | −6.41% |
| 2020 | 2020-12-31 | $826.8M | −$30.6M | −3.56% |
| 2019 | 2019-12-31 | $857.4M | −$23.2M | −2.63% |
| 2018 | 2018-12-31 | $880.6M | −$18.1M | −2.01% |
| 2017 | 2017-12-31 | $898.6M | $429.1M | +91.38% |
| 2016 | 2016-12-31 | $469.6M | −$1.0M | −0.22% |
| 2015 | 2015-12-31 | $470.6M | −$13.0M | −2.68% |
| 2014 | 2014-12-31 | $483.5M | — | — |
Kyntra Bio quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $101.1M | −$77.0M | −43.23% |
| Q1 2026 | 2026-03-31 | $109.6M | −$55.6M | −33.64% |
| Q4 2025 | 2025-12-31 | $119.6M | −$94.9M | −44.25% |
| Q3 2025 | 2025-09-30 | $137.0M | −$127.4M | −48.18% |
| Q2 2025 | 2025-06-30 | $178.1M | −$115.1M | −39.27% |
| Q1 2025 | 2025-03-31 | $165.2M | −$200.7M | −54.84% |
| Q4 2024 | 2024-12-31 | $214.5M | −$209.0M | −49.35% |
| Q3 2024 | 2024-09-30 | $264.4M | −$196.0M | −42.57% |
| Q2 2024 | 2024-06-30 | $293.2M | −$221.9M | −43.08% |
| Q1 2024 | 2024-03-31 | $365.9M | −$172.7M | −32.06% |
| Q4 2023 | 2023-12-31 | $423.5M | −$186.6M | −30.58% |
| Q3 2023 | 2023-09-30 | $460.4M | −$148.4M | −24.38% |
| Q2 2023 | 2023-06-30 | $515.1M | −$171.7M | −24.99% |
| Q1 2023 | 2023-03-31 | $538.5M | −$207.4M | −27.80% |
| Q4 2022 | 2022-12-31 | $610.1M | −$163.7M | −21.16% |
| Q3 2022 | 2022-09-30 | $608.8M | −$241.7M | −28.42% |
| Q2 2022 | 2022-06-30 | $686.8M | −$121.8M | −15.07% |
| Q1 2022 | 2022-03-31 | $745.9M | −$41.4M | −5.25% |
| Q4 2021 | 2021-12-31 | $773.8M | −$53.0M | −6.41% |
| Q3 2021 | 2021-09-30 | $850.5M | $38.5M | +4.74% |
| Q2 2021 | 2021-06-30 | $808.6M | $935,000 | +0.12% |
| Q1 2021 | 2021-03-31 | $787.3M | −$37.1M | −4.50% |
| Q4 2020 | 2020-12-31 | $826.8M | −$30.6M | −3.56% |
| Q3 2020 | 2020-09-30 | $812.0M | −$81.9M | −9.17% |
| Q2 2020 | 2020-06-30 | $807.7M | −$107.4M | −11.74% |
| Q1 2020 | 2020-03-31 | $824.4M | $12.0M | +1.47% |
| Q4 2019 | 2019-12-31 | $857.4M | −$23.2M | −2.63% |
| Q3 2019 | 2019-09-30 | $894.0M | $38.3M | +4.48% |
| Q2 2019 | 2019-06-30 | $915.1M | $45.1M | +5.19% |
| Q1 2019 | 2019-03-31 | $812.4M | −$55.2M | −6.36% |
| Q4 2018 | 2018-12-31 | $880.6M | −$18.1M | −2.01% |
| Q3 2018 | 2018-09-30 | $855.6M | −$39.3M | −4.39% |
| Q2 2018 | 2018-06-30 | $869.9M | $327.3M | +60.31% |
| Q1 2018 | 2018-03-31 | $867.6M | $425.9M | +96.40% |
| Q4 2017 | 2017-12-31 | $898.6M | $429.1M | +91.38% |
| Q3 2017 | 2017-09-30 | $894.9M | $408.7M | +84.05% |
| Q2 2017 | 2017-06-30 | $542.6M | $43.5M | +8.72% |
| Q1 2017 | 2017-03-31 | $441.8M | −$779,000 | −0.18% |
| Q4 2016 | 2016-12-31 | $469.6M | −$1.0M | −0.22% |
| Q3 2016 | 2016-09-30 | $486.2M | −$13.0M | −2.61% |
| Q2 2016 | 2016-06-30 | $499.1M | −$42.3M | −7.81% |
| Q1 2016 | 2016-03-31 | $442.5M | $7.0M | +1.61% |
| Q4 2015 | 2015-12-31 | $470.6M | −$13.0M | −2.68% |
| Q3 2015 | 2015-09-30 | $499.2M | — | — |
| Q2 2015 | 2015-06-30 | $541.4M | — | — |
| Q1 2015 | 2015-03-31 | $435.5M | — | — |
| Q4 2014 | 2014-12-31 | $483.5M | — | — |
Kyntra Bio total assets trends
Over the last five fiscal years, Kyntra Bio's total assets decreased from $826.8M to $119.6M, a change of −$707.2M. The latest reported quarter, Q2 2026, shows $101.1M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kyntra Bio source filings ↗